N/A
N=69
Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)
Mild Cognitive Impairment · Dementia
Bottom Line
View on ClinicalTrials.gov: NCT02544074 ↗Enrolled (actual)
69
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcome: Primary: eSAGE Score Compared to the Sum of the Neuropsychological Measures. — 0.7292 spearman rank correlation
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- neuropsychological testing (Behavioral); eSAGE testing (Behavioral)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Ohio State University
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY eSAGE Score Compared to the Sum of the Neuropsychological Measures. |
0.7292 | — |
| SECONDARY eSAGE Score Compared to the Paper SAGE Score |
0.8824 | — |
| SECONDARY eSAGE Score Compared to the Mini-Mental State Examination (MMSE) Score |
0.6711 | — |
| SECONDARY eSAGE Score Compared to the Montreal Cognitive Assessment (MoCA) Score |
0.7577 | — |
| SECONDARY eSAGE Score Compared to the Boston Naming Test Score |
0.3487 | — |
| SECONDARY eSAGE Score Compared to the Wisconsin Card Sort Task (WCST) Score |
0.4596 | — |
| SECONDARY eSAGE Score Compared to the Hopkins Verbal Learning Test (HVLT) Score |
0.6045; 0.4866 | — |
| SECONDARY eSAGE Score Compare to the FAS Verbal Fluency Task Score |
0.3210 | — |
| SECONDARY eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Letter-number Score |
0.5349 | — |
| SECONDARY eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Block Design Score |
0.5774 | — |
Summary
The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia. SAGE's self-administered feature, pen and paper format, and four equivalent interchangeable forms allows it to be given in almost any setting, does not require any staff time to administer and makes it practical to rapidly screen large numbers of individuals in the community or in their home.This trial is being conducted to study the validity of SAGE in a digital format (eSAGE) for cognitive screening.
The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.
Addendum:
The eSAGE was previously validated in an earlier stage of this trial. It was initially designed for tablet use and the exact same test has recently been formatted for smartphone use.
This addendum is being conducted to study the validity of the smartphone eSAGE compared to the tablet eSAGE for cognitive screening.
Eligibility Criteria
Inclusion Criteria
- Adults over 49 years old of either gender
- Vision and hearing sufficient for compliance with tests
Exclusion Criteria
- Diagnosis by a physician of moderate or severe dementia
- Intellectual disability
Data sourced from ClinicalTrials.gov (NCT02544074). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.